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Abstract
Background: Gastric cancer samples obtained by histologic macrodissection contain a relatively high stromal
content that may significantly influence gene expression profiles. Differences between the gene expression
signature derived from macrodissected gastric cancer samples and the signature obtained from isolated gastric
cancer epithelial cells from the same biopsies using laser-capture microdissection (LCM) were evaluated for their
potential experimental biases.
Methods: RNA was isolated from frozen tissue samples of gastric cancer biopsies from 20 patients using both
histologic macrodissection and LCM techniques. RNA from LCM was subject to an additional round of T7 RNA
amplification. Expression profiling was performed using Affymetrix HG-U133A arrays. Genes identified in the
expression signatures from each tissue processing method were compared to the set of genes contained within
chromosomal regions found to harbor copy number aberrations in the tumor samples by array CGH and to
proteins previously identified as being overexpressed in gastric cancer.
Results: Genes shown to have increased copy number in gastric cancer were also found to be overexpressed in
samples obtained by macrodissection (LS P value < 10
-5), but not in array data generated using microdissection. A
set of 58 previously identified genes overexpressed in gastric cancer was also enriched in the gene signature
identified by macrodissection (LS P <1 0
-5), but not in the signature identified by microdissection (LS P = 0.013). In
contrast, 66 genes previously reported to be underexpressed in gastric cancer were enriched in the gene signature
identified by microdissection (LS P <1 0
-5), but not in the signature identified by macrodissection (LS P = 0.89).
Conclusions: The tumor sampling technique biases the microarray results. LCM may be a more sensitive collection
and processing method for the identification of potential tumor suppressor gene candidates in gastric cancer
using expression profiling.
Background
A major aim of microarray analysis is the identification
of differentially expressed genes in subsets of clinical
samples to match specific therapies to tumor subtypes.
However, quantitative expression array analysis of clini-
cal cancer samples with high stromal content is challen-
ging since the ratio of epithelial tumor cells to stromal
cells can vary greatly. Contaminating stroma may
confound microarray-based expression and copy number
analyses. Laser capture microdissection (LCM) is a valu-
able technique that enables one to isolate epithelial cells
from stromal cells, thus enriching for epithelial content.
T h eq u a n t i t yo fs a m p l ea n dR N Ao b t a i n e db yL C Mi s
often quite limited, however, and requires an amplifica-
tion step to generate sufficient material for microarray
analyses. This amplification process may bias the results
and lead to a skewed set of differentially expressed
genes [1]. Histologic macrodissection (samples collected
from tissue sections guided by microscopic analysis of a
stained serial section) provides a larger amount of
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need for an additional round of RNA amplification.
However, macrodissected samples contain significantly
more stromal cell content than samples obtained by
microdissection.
Previous studies have compared these two tissue pro-
cessing methods for clinical cancer samples. Based upon
data from 14 rectal adenocarcinoma samples, Bruin et
al. favored macrodissection over microdissection
because of the relatively low contribution of stromal
components in macrodissected samples from this tumor
type and the biased gene expression results from micro-
dissected samples due to the amplification of the RNA
required for these samples [2]. On the other hand, Klee
et al. suggested that microdissection profiling uniquely
identify a large number of differentially expressed genes
not otherwise found using bulk tissue sampling, based
on data from 10 lung adenocarcinomas and 6 adjacent
normal samples [3]. These studies were limited by small
sample sizes, and, therefore, require further validation. It
is also unclear whether the genes identified uniquely
using microdissected samples represent useful biomar-
kers. Bias resulting from RNA amplification must be
balanced against the benefit of enriching samples for
epithelial content in considering whether microdissec-
tion is advantageous for expression profiling of tumors
with high stromal content, such as gastric or pancreatic
adenocarcinomas.
Microdissection is particularly useful for enriching
gastric cancer tumor cells obtained from endoscopic
biopsy samples, especially from diffuse-type gastric can-
cer which is composed of scattered tumor cells mixed
with inflammatory cells and fibrosis. The decline in
overall incidence of gastric carcinoma in U.S. during
this century appears to be largely attributable to a
decrease of the intestinal type lesions, while the occur-
rence of diffuse type is thought to have remained the
same [4]. Using samples obtained by LCM, Wu et al.
reported that malignant versus benign gastric epithelial
cells could be distinguished with an accuracy of 99%
based upon a 504 gene predictor [5]. This predictor
included well-known genes expressed in the gastric
epithelium including Trefoil factors 1, 2, and 3 [5].
Using LCM, Jinawath et al. identified 46 genes that may
represent distinct molecular signatures for the two his-
tological types of gastric cancer - diffuse-type and intest-
inal-type gastric cancers [6]. However, no studies have
been performed to date directly comparing the macro-
dissection vs. LCM methods using the same set of gas-
tric cancer samples.
In this study, we have sought to evaluate the distinc-
tions between expression profiles derived from the same
tumors that were processed by both macrodissection
and LCM for microarray analyses. Given the difficulty in
validating all of the differentially expressed genes identi-
fied using each type of sample collection, we compared
the genes identified through our microarray analyses
with proteins known to be overexpressed in gastric can-
cer. Additionally, we determined whether expression of
genes identified in each signature correlated with altera-
tions in the gene copy number that were identified by
array comparative genomic hybridization (CGH) from
the same tumors. Previous studies of gastric cancer have
demonstrated a high correlation between array CGH
and expression array data [7]. Copy number changes
were evaluated using macrodissected tumor DNA in
order to avoid the bias from whole genome amplifica-
tion. We further determined whether the gene signa-
tures we obtained from each sample collection and
processing method were enriched for proteins that have
previously been reported to be dysregulated genes in
gastric cancer. Our results indicate that the LCM
method is more sensitive for identifying genes that are
underexpressed in the cancer compared to normal tissue
(potential tumor suppressors), whereas macrodissection
identifies more genes that are overexpressed in cancer.
Therefore, macrodissection and LCM microdissection
appear useful for studying different aspects of cancer
biology.
Methods
Patients
Twenty patients who were analyzed in this study is a
part of 96 patients who participated in a prospective
study and whose samples were used as an expression
training set to develop a chemo-response predictor [8].
Part of expression and CGH array data from their
macrodissected samples was previously reported [8,9].
Sample collection, treatment, and follow-up were per-
formed according a protocol approved by the Institu-
tional Review Board (IRB) of the National Cancer
Center Hospital in Goyang, Korea (NCCNHS01-003).
All patients signed an IRB-approved informed consent
form. Eligibility for enrollment into the study included
the following parameters: 1) age ≥ 18 years; 2) histologi-
cally-confirmed gastric adenocarcinoma; 3) clinically-
documented distant metastasis; 4) no previous or conco-
mitant malignancies other than the gastric cancer; 5) no
prior history of chemotherapy, either adjuvant or pallia-
tive; and 6) adequate function of all major organs.
Patients received cisplatin 60 mg/m
2 IV on day 1 and
fluorouracil 1,000 mg/m
2 I Vo nd a y s1 - 5o fa3 - w e e k
schedule.
Tissue processing
Before macrodissection, tumor samples had median
tumor nuclei of 50% (interquartile range, 30-60%).
Macrodissection was performed as previously described
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nuclei at top slide (interquartile range, 60-72.5%). For
microdissection, tumor and normal tissue sample cryo-
sections were cut at 10 μm ,a n ds t o r e df r o z e na t- 8 0 ° C .
Slides were dehydrated using nuclease-free HistoGene
(Molecular Devices, Sunnyvale, CA) reagents according
to the manufacturer’s recommendations. Microdissec-
tion was performed using PixCell II (Arcturus
Bioscience, Mountain View, CA). Dehydration and LCM
was limited to 15 min or less for each sample collected.
A total of 10,000 laser shots (spot size of 15 μmi nd i a -
meter) were collected using CapSure Macro LCM Caps
for each sample. RNA was isolated using PicoPure RNA
Isolation Kit (Molecular Devices). Briefly, the epithelial
cells were incubated with 50 μL of extraction buffer in a
0.5 mL microcentrifuge tube at 42°C for 30 min. DNase
(QIAGEN, Valencia, CA) treatment was performed
directly within the purification column, and the RNA
was isolated using the elution volume of 8 μL (Molecu-
lar Devices). Five μL of RNA from microdissected cell
populations was converted to biotinylated, antisense
cRNA target, using the Affymetrix two-cycle labeling
method (Santa Clara, CA). All biotinylated targets were
fragmented and 15μg of each was hybridized to HG-
U133A GeneChip microarrays following the manufac-
turer’sp r o t o c o l .S c a n n e da r r a yi m a g e sw e r er e v i e w e d
and converted to signal data using the Affymetrix MAS
5.0 algorithm.
Array CGH
Genomic DNA was extracted from samples using TRI
reagent (Invitrogen, Carlsbad, CA), according to the
manufacturer’s protocol, and additionally purified using
the QIAamp DNA Micro Kit (QIAGEN). For array
CGH experiments, Agilent 4x44k HD-CGH Microarrays
containing 44,000 features (Agilent Technologies, Santa
Clara, CA) were used. 0.5-1 μgo ft u m o rg e n o m i cD N A
samples and the same amount of human genomic DNA
from multiple anonymous female donors (Promega,
Madison, WI) were digested with AluI (50 units) and
R s a I( 5 0u n i t s )f o r2ha t3 7 ° C .5μl of Random Primer
was mixed with the digested DNA template. The refer-
ence and sample DNA were labeled using Agilent’s
Labeling Kit PLUS, which includes 5x buffer, 10x dNTP,
Cy-3/5 dUTP (1.0 mM), and Exo-Klenow Fragment.
T h ep r o b em i x t u r eo fC y 3l a b e l e ds a m p l eD N A ,C y 5
labeled reference DNA (39 μl), 5 μl of human Cot-1
DNA (Invitrogen), 11 μl of Agilent 10 × blocking agent
and 50 μl of Agilent 2 × hybridization buffer was dena-
tured at 95 °C for 3 min and incubated at 37 °C for 30
min. The probe was applied to the array using an Agi-
lent microarray hybridization chamber, and hybridized
for 21 h at 65°C in a rotating oven at 20 rpm. Arrays
were washed according to the manufacturer’s
recommendations, dipped in Agilent’ss t a b i l i z i n ga n d
drying solution, and scanned using an Agilent 2565AA
DNA microarray scanner. The Agilent’sS c a nP r o g r a m
Control Program 7.0 and Agilent’s Feature Extraction
Software Program 9.5.1 were used for data processing.
Array CGH data were analyzed using Agilent’sC G H
Analytics software (version 3.5.14). ADM-2 algorithm
with threshold 6, with fuzzy zero and centralization on,
was used to identify aberration. Criteria for aberration
filtering were minimum probes of 5, minimum average
absolute log2 ratio of 0.5, and maximum aberrations of
1,000,000. Aberrations identified for each sample were
listed and graphically displayed.
Gastric cancer genes in the literature
To generate a user-defined gene set for our gene com-
parison analyses, we searched PubMed database for
genes with gastric cancer cell-specific protein expres-
sion, using keywords of “gastric cancer”, “immunohisto-
chemistry” and “overexpressed” or “loss of expression”.
For our gene set comparison analyses, gene symbols of
gastric cancer specific genes were mapped to probe set
IDs on the HG-U133A array (http://www.NetAffx.com).
There were 178 ("overexpressed”) and 327 ("loss of
expression”) articles in the Pubmed at the time of
writing.
Statistical analysis on expression array data
Affymetrix HG-U133A gene expression microarray data
were analyzed with gene set comparison analysis algo-
rithms of BRB ArrayTools (version 3.8, National Cancer
Institute, http://linus.nci.nih.gov/BRB-ArrayTools.html)
[11]. The gene set comparison tool analyzes user-
defined gene sets for differential expression among pre-
defined classes (i.e., cancer vs. normal) of a source data-
set. User-defined gene sets used in this study include
U133A probe sets corresponding to genes with copy
number change and corresponding to gastric cancer
genes in the literature. Genes whose tumor/normal log2
ratio is higher than 0.5 in at least one of 20 patient sam-
ples were included in the list of genes with copy number
gain. Similarly, genes with copy number loss (log2 ratio
< -0.5) were listed. These user-defined gene sets were
analyzed for differential expression between 20 cancer
samples and 6 normal samples (i.e., 3 macrodissected
and 3 microdissected samples).
For each source dataset, a P-value is computed for
each gene to correlate the expression level for the differ-
ential expression between pre-defined classes, generating
a ranked gene list of a given BRB-ArrayTools project.
For a set of N genes, the least squares (LS) statistic is
defined as the mean negative natural logarithm of the P-
values of the appropriate single gene univariate tests
[12]. A summary statistic is computed that summarizes
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mary statistic is average log(P)f o rt h eL Ss u m m a r yo f
how the P values differ from a uniform distribution for
LS [12]. The summary statistic is related to the distribu-
tion of the summary statistics for random samples of N
genes, sampled from those represented on the array.
Here N is the number of genes in the user-defined gene
set. 100,000 random gene sets were sampled to compute
this distribution. The LS P value is the proportion of
random sets of N genes with smaller average summary
statistics than the LS summaries computed for the real
data.
BRB-ArrayTools estimated LS P values for enrichment
of the 4 gene sets in our gastric cancer transcriptome
signature identified by each tissue processing method as
follows. First, in order to compare the 2,324 genes asso-
ciated with copy number gain with our gastric cancer
transcriptome signature identified by the microdissec-
tion, the LS statistic of 2,324 amplified genes was esti-
mated by computing a mean negative natural logarithm
of the P values of the single gene univariate tests for dif-
ferential expression of each of 2,324 genes between 20
microdissected gastric cancer samples and 6 normal
samples. Then BRB-ArrayTools calculated the propor-
tion of random sets of 2,324 genes with smaller average
summary statistics than the LS summaries computed for
t h er e a ld a t a( L SP value). The gastric cancer transcrip-
tome signature identified by the microdissection was
also compared with 677 genes associated with the copy
number loss, 58 proteins reported to be overexpressed
in gastric cancer, and 66 proteins reported to be under-
expressed in gastric cancer, with respective LS P values.
LS P value less than 0.01 was considered significant.
The same analyses were repeated for gastric cancer tran-
scriptome signature identified by the macrodissection
method.
Immunohistochemistry
TFF1 immunohistochemistry was performed using sur-
gical or endoscopic biopsy tissue samples from 16 gas-
tric cancer patients (16 cancer and 2 adjacent normal
tissue samples), and 4 healthy volunteers, who were not
included in this DNA microarray study. Grossly-normal
gastric mucosa tissue samples were collected from the
gastric antrum of healthy volunteers using a blind
biopsy technique, with informed consent [9]. Paraffin-
embedded formalin-fixed tissue slides (4 μm thick) were
stained with 13734-1-AP (ProteinTech Group, Chicago,
I L )a t1 : 5 0f o r6 0m i na tr o o mt e m p e r a t u r ea n dE n v i -
sion anti-rabbit horseradish peroxidase (K4003, DAKO,
Carpinteria, CA) for 30 min at RT. The reaction was
visualized using diaminobenzidine (K3468, DAKO) and
counterstained with hematoxylin. TFF1 expression was
evaluated semi-quantitatively at 200x magnification,
based on percentage of positively stained cells ("-” =
immunostaining in ≤ 10% of cells; “+” =1 1 - 5 0 % ;“++” =
51-75%; “+++” = 76-100%) [13,14]. Immunostaining
without primary antibody and normal gastric epithelium
of a control tissue microarray served as negative and
positive controls, respectively [15]. Cytoplasmic stain
which was unequivocally deeper than background was
counted as positive.
Results
Determination of global gene expression signatures from
macrodissected and LCM samples
Table 1 delineates the clinico-pathological characteristics
of the patients and volunteers included in this microar-
ray study. Microarray data was obtained for both LCM
and macrodissected samples from the same 20 biopsies
(Figure 1A). Although of acceptable quality, microarray
data from LCM samples had generally lower “present
call” than macrodissected samples (data not shown).
Principal component analysis of the global gene expres-
sion patterns derived from the micro- and macro-dis-
sected gastric cancers, and the normal samples
Table 1 Clinico-pathological characteristics of patients
and volunteers included in microarray analysis
Patients (n = 20) Volunteers (n = 6)
Baseline clinico-pathological characteristics
Age-year
Median 59 52
Interquartile range 54-69 43-61
Sex - no. (%)
Male 16 (80%) 3 (50%)
Female 4 (20%) 3 (50%)
Performance status (PS) - no. (%)
ECOG1 PS 0 or 1 20 (100%)
Histological type - no. (%)
Lauren’s intestinal 6 (30%)
Lauren’s diffuse 14 (70%)
Location of primary lesion - no. (%)
Upper 1/3 4 (20%)
Middle 1/3 6 (30%)
Lower 1/3 10 (50%)
Distant metastasis - no. (%) 20 (100%)
Treatment and outcome
Chemotherapy regimen - no. (%)
Cisplatin/Fluorouracil 20 (100%)
Overall survival - month.
Median 8.0
Interquartile range 5.6-14.7
Time to progression - month.
Median 3.5
Interquartile range 2.3-6.2
1Eastern Cooperative Oncology Group
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(Figure 1B). The median Pearson correlation between
the two processing methods was 0.75 (interquartile
range, 0.71-0.81).
Tables 2 and 3 show genes overexpressed in micro-
and macro-dissected gastric cancer samples at feature
selection P <1 0
-6. Cell morphology (AIF1,E2F1, E2F3,
KIR2DL1, KIRREL, NPR1, RUNX2, TRIO)w a st h em o s t
enriched functional category of the 42 genes overex-
pressed in the microdissected samples compared to the
normal samples (feature selection P <1 0
-6)a si d e n t i -
fied by Ingenuity Pathway Analysis (IPA) (Table 2).
Tumor morphology (APOE, BIRC5, CD14, COL1A1,
COL1A2, CYR61, FKBP1A, IL8, MCAM, MIF, RHOB)
was the most enriched functional category among the
73 genes overexpressed in the macrodissected samples
(feature selection P <1 0
-6) by IPA (Table 3). Extracel-
lular matrix genes, such as COL6A2, COL1A1,
COL1A2,a n dCOL5A2, were prominent in the macro-
dissected samples and presumably contributed by the
stromal cells. Table 4 shows genes underexpressed in
micro- and macro-dissected gastric cancer samples at
feature selection P <1 0
-6.
Comparison between expression and array CGH data
Array CGH analysis was performed using genomic DNA
extracted from macrodissected samples containing > 50%
tumor cells (criteria used by previous studies [16,17]) since
sufficient DNA could be obtained without the need for
whole genome amplification as required for microdis-
sected samples. Whole genome DNA amplification may
potentially introduce artifactual bias in array CGH results
[18]. Depicted in Figure 2 is the frequency of DNA copy
number aberrations among all of the 20 samples. Our
copy number aberration data was generally consistent
with previously reported data [7,16,17,19-23]. Four of 20
patients had amplification of chr8 q24.13-q24.21
(126357475-128822596) which contains the MYC onco-
gene. The second most common amplification locus was
chr17 q21.2 (36109939-36230163) which was amplified in
3 patients. Seven patients had no detectable chromosome
aberrations. These 7 samples contained a median of 70%
Figure 1 (A) Study scheme of sample collection and microarray processing (B) Principal component analysis of gene expression
profiles of micro- and macro-dissected tumor samples from 20 gastric cancer patients and 6 normal samples from healthy volunteers.
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Page 5 of 11tumor cells, while the other 13 patients had a median 60%
tumor cells (P value = 0.1). Hence, the lack of detectable
chromosome aberrations in the 7 samples was not due to
a lower percentage of tumor cells in those samples.
There were 2,324 unique genes which were associated
with copy number gain in at least one of the 20 patients,
and 677 genes associated with copy number loss. Using
gene set comparison analyses, we compared these gene
sets with our transcriptome signatures identified by the
different sample isolation methods. We hypothesized
that dysregulated genes associated with copy number
aberrations are more likely to be involved as contribu-
tors to oncogenesis rather than simply as “bystanders.”
Hence, the 2,324 genes contained within regions of copy
number gains were analyzed with regard to their expres-
sion from array data obtained using the macrodissection
method (feature selection P <0 . 0 5 ) .T h eo v e r l a p
between the list of genes in regions of amplification and
enrichment for their expression in samples that were
macrodissected was statistically significant (LS P value =
10
-5; see Methods for statistical description). However,
this association was not observed when expression data
was analyzed from microdissected samples (feature
selection P < 0.05; LS P value = 0.41) (Figure 3A). Thus,
there was stronger association between the pattern of
copy number gain and gene expression only in samples
that were macrodissected. For example, MYC,t h em o s t
frequently amplified gene in our patient samples, was
determined to be significantly overexpressed in macro-
dissected samples, but not in those that were microdis-
sected, although this result may be due to relatively
small sample size or heterogeneity within the tumor.
A list of 677 genes was identified in regions where DNA
copy number loss was found in at least one of the 20 study
patients. The expression of these genes was analyzed in the
macro- and micro-dissected array datasets. A significant
Table 2 Genes overexpressed in microdissected gastric
cancer at feature selection P <1 0
-6
Gene FC
1 Gene FC
BMP3 38.5
2 HIST1H4C 6.3
BGN 30.3 LEPRE1 5.9
TRIO 18.5 ETNK2 5.6
GADD45GIP1 17.2 TRIP6 5.3
MIER2 16.7 FAM125B 5.3
KIFC3 16.4 NPR1 5.3
217318_x_at 13.7 DSCC1 5.3
217219_at 13.2 CLUL1 5.0
RUNX2 12.5 HMGB3 4.5
SMARCD1 12.0 E2F3 4.3
KIRREL 12.0 AIMP2 4.2
215621_s_at 12.0 ATAD5 4.0
GRM2 10.0 E2F1 3.8
FJX1 10.0 FKSG49 3.7
AIF1 10.0 DVL2 3.7
THY1 9.1 TIPRL 2.9
CARD10 9.1 EIF2C3 2.9
SIM2 9.1 NAT10 2.8
AIF1 9.1 MED27 2.7
APOBEC3G 8.3 PIN4 2.7
RHAG 8.3 CTPS 2.6
1fold change, defined by the expression ratio of cancer to normal (= cancer/
normal)
2All these genes had false discovery rate <0.001.
Table 3 Genes overexpressed in macrodissected gastric
cancer at feature selection P <1 0
-6
Gene FC
1 Gene FC
LY6E 24.4
2 SRM 6.7
IL8 22.7 NGLY1 6.7
CA12 20.0 RHOB 6.3
SBNO2 19.2 ACTN1 5.9
UBE2S 17.2 LOXL2 5.9
CYR61 17.2 COL5A2 5.9
ANGPT2 15.9 TRIM28 5.6
COL6A2 14.3 218982_s_at 5.6
BOP1 13.2 C7orf44 5.3
COL1A1 13.2 UBE2C 5.3
LPL 13.0 CEP76 5.3
MFGE8 12.8 BIRC5 5.3
APOE 12.2 PNO1 5.0
G6PC3 10.9 FSTL1 5.0
215900_at 10.3 GRINA 4.8
NUP62 10.0 MRTO4 4.8
MRPL4 10.0 STC1 4.8
GNL3L 10.0 MRPL12 4.5
MCAM 9.1 FKBP1A 4.5
PDLIM7 9.1 IFI30 4.5
216472_at 9.1 KPNA6 4.3
ACTN1 9.1 216532_x_at 4.3
BYSL 9.1 CENPI 4.2
GNAI2 8.3 PPM1G 4.2
NCAPH2 8.3 ICT1 3.7
CD14 8.3 SFRS14 3.6
EXOSC4 8.3 CTPS 3.6
OBFC2B 8.3 IMP4 3.3
PPP1R15A 7.7 UBE2G2 3.2
COL1A2 7.7 ISG20L2 3.2
GPX1 7.7 EIF4A1 3.1
MIF 7.7 HDGF 2.6
NME1 7.1 PSMD14 2.6
PPIL2 7.1 220856_x_at 2.4
CCDC85B 7.1 CNOT3 2.4
SPARC 6.7 GLT25D1 2.0
C8orf55 6.7
1fold change, defined by the expression ratio of cancer to normal (= cancer/
normal)
2All these genes had false discovery rate <0.001.
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number and their expression in both macro- and micro-
dissected samples. (LS P values, 0.009 and 0.006 for LCM
and macrodissected samples, respectively) (Figure 3B).
Concordance of gene signatures with genes previously
reported to be associated with gastric cancer
A PubMed literature search was performed to identify
previously reported over- and under-expressed genes
and proteins for gastric cancer (keywords: immunohisto-
chemistry, gastric cancer, and overexpressed and or loss
of expression). 58 proteins overexpressed in gastric can-
cer were identified in this manner. Gene expression for
these 58 proteins were found to be enriched in expres-
sion data from samples collected by macrodissection (LS
P <1 0
-5) ,b u tn oe n r i c h m e n ti ne x p r e s s i o no ft h e5 8
genes was found for samples collected by microdissec-
tion (LS P = 0.013). In contrast, 66 proteins reported to
be underexpressed in gastric cancer were enriched in
expression array data from samples collected by micro-
dissection (LS P <1 0
-5), but not from samples collected
by macrodissection (LS P = 0.89) (Table 5).
Validation of microarray data
In order to validate our microarray data, we performed
immunohistochemical analyses on a gene identified as
underexpressed in microdissected cancer samples from 16
patients and 4 volunteers who were not included in DNA
microarray study. TFF1 was chosen for this immunohisto-
chemistry validation study, because it is significantly
underexpressed in the LCM samples (P = 0.0036) but not
in macrodissected samples (P =0 . 0 9 ) ,a sc o m p a r e dw i t h
normal gastric mucosa. TFF1 immunoreactivity in cancer
was evaluated as -, +, ++, and +++ in 7 (43.8%), 3 (18.7%),
4 (25.0%), and 2 (12.5%), respectively. In contrast, all of
the 6 normal gastric mucosa samples (4 healthy volunteers
and 2 normal adjacent tissue samples) preserved TFF1
immunoreactivity (+++) (Figure 4). Thus, gastric cancer
samples had significantly lower TFF1 immunoreactivity
than normal gastric mucosa, consistent with previous
reports [13,14] (P for chi-square = 0.007).
These results demonstrate that macrodissection-based
gene expression analyses outperformed gene expression
analyses from LCM samples for identifying genes over-
expressed in gastric cancer. In contrast, microdissection
outperformed macrodissection for the identification of
possible gastric cancer tumor suppressor genes.
Discussion
Although limited by a relatively small sample size, this
study demonstrates the feasibility of LCM as a tissue
collection and processing method for gastric cancer
samples with high stromal content. Gene signatures
identified from microdissected samples were moderately
correlated with signatures identified from macrodis-
sected samples from the same biopsy samples. Most
genes previously found to be associated with gastric can-
cer were identified in the signatures from both sets of
samples (LS P value < 0.001 for both sets). Importantly,
microdissection was found to be a better tissue proces-
sing technique than macrodissection for identifying
down-regulated genes including potential tumor sup-
pressor genes in gastric cancer.
Table 4 Genes underexpressed in micro- and macro-
dissected gastric cancer at feature selection P <1 0
-6
Microdissected Macrodissected
Gene FC
1 Gene FC
HPGD -25.0
2 208498_s_at -11.1
HRASLS2 -20.0 SIDT2 -7.7
ABCC3 -20.0 MUC5AC -5.9
SLC25A37 -16.7 CTAGE5 -5.0
ABHD2 -14.3 GNA11 -3.8
VIPR1 -10.0 ARFIP1 -3.4
CYTIP -9.1 214316_x_at -3.3
GALNT6 -9.1 222149_x_at -3.3
SULT1A2 -9.1
OAS1 -8.3
PDCD4 -7.1
NR3C2 -7.1
DOCK6 -6.3
SULT1A1 -5.9
ZFYVE26 -5.9
213212_x_at -5.6
DSCR3 -5.3
TMEM131 -5.3
ECHDC2 -5.0
DENND1B -5.0
KIAA0141 -4.8
RNF103 -4.8
PDCD4 -4.5
CABIN1 -4.5
222371_at -4.3
RRBP1 -4.0
CC2D1A -3.8
216438_s_at -3.8
SGSM3 -3.8
ARPC2 -3.7
TRAK1 -3.6
GNA11 -3.6
PAFAH1B1 -3.4
CNDP2 -3.2
SPOP -3.1
PARP4 -3.1
ERLIN1 -2.9
1fold change, defined by the negative of the expression ratio of normal to
cancer (= - (normal/cancer))
2All these genes had false discovery rate <0.001.
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were enriched for genes that were overexpressed,
including potential oncogenes, compared to samples
obtained by microdissection .T h i sm a yb ed u e ,i np a r t ,
to the inherent biases introduced by RNA amplification
for LCM samples. The relative disadvantage of microdis-
section in identifying genes overexpressed in cancer may
be related to the fact that an additional round of RNA
amplification, required for processing microdissected
samples, is associated with 30% transcript loss [1]. It is
also possible that macrodissected samples contain a lar-
ger amount of tumor sample and, thus, capture a
greater degree of molecular heterogeneity of the tumor
compared to LCM samples. Thus, it would be more
likely to include regions with increased gene expression
in macrodissected samples compared to LCM samples.
Additionally, macrodissected samples may contain nor-
mal stomach epithelium that expresses sufficiently large
amounts of a gene as to mask the loss of gene expres-
sion in the tumor cells within the sample. Further,
macrodissected samples include a significant portion of
stromal cells that would express many additional genes
not expressed in the epithelial components of the
tumor. Our data, however, needs to be interpreted with
Figure 2 Graphic image illustrating the percent frequency of probes detected (aberrations) among all 20 samples.
Figure 3 Number of genes overlapping between LCM and macrodissected expression array datasets and array CGH data from the
same set of 20 patients.
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Page 8 of 11some caution. Most of the genes within amplicons or
previously identified as being overexpressed in gastric
cancer exhibited a prominent (>2-fold) up-regulation by
microarray in the cancer samples compared to normal
controls. Since the macrodissected samples contained >
50% tumor cells, the most prominent changes in gene
expression are likely identified using the macrodissected
samples. However, more subtle increases in gene expres-
sion could have been missed.
In addition to providing more robust information
about highly up-regulated genes in cancer cells, macro-
dissection has the advantage of providing important
information from stoma. It has become clear that both
the epithelial and stromal components of a tumor inter-
act in important ways to determine the biologic proper-
ties of the cancer. Accumulating evidence suggests that
alterations in the expression of genes in the stroma pro-
vide important prognostic information [24,25]. However,
the limitation in sample size of this study did not allow
us to compare the potential prognostic values of the sig-
natures we identified using the two tissue processing
methods.
On the other hand, samples obtained by microdissec-
tion were enriched for genes whose expression was
reduced in the tumor samples compared to normal
gastric epithelial cells. The downregulated genes we
identified are in keeping with genes whose expressions
have been reported to be reduced in gastric cancer.
Therefore, microdissected samples appear better suited
for identifying genes whose expression is reduced in gas-
tric cancer, some of which may be potential tumor sup-
pressor genes. This finding is consistent with the
previous observation of Klee et al. that substantially
more downregulated genes were uniquely identified in
the LCM dataset than identified in the bulk dataset [3].
These authors suggested that this is reflective of the cell
population sampled rather than amplification bias since
this effect was not observed in the array data generated
using linearly amplified bulk tumor RNA. Whether
those genes that were uniquely identified in the LCM
datasets are truly biologically significant genes or an
artifact arising from the LCM process was not fully eval-
uated by DNA- or protein-based studies [3]. Tomlins et
al. also reported that LCM cell sampling in prostate
cancer minimized the strong contaminating influence of
Table 5 Gastric cancer genes in the literature that were
differentially expressed between 20 cancer and 6 normal
samples at feature selection P < 0.05 according to
microarray data generated using each tissue processing
method
Overexpressed genes in cancer Underexpressed genes in cancer
LCM&Macro
1 LCM Macro LCM&Macro LCM
2 Macro
APOE EGFR AKT1 ANXA10 ANXA7 CDKN2B
AURKA HGF ANXA2 CASP6 BAD FHIT
CCNE1 MET CALR CASP7 HLA-B
CDC20 RHOA CCNB1 CDH1 HLA-E
CDC25B TNS4 EEF2 CTNNA1 HLA-G
CXCR4 ESM1 GSN PRSS8
E2F1 HIF1A HLA-F PTEN
EGR1 MINA IQGAP2 SDHB
GRB2 PHB KCNE2 SH3GLB1
HK2 KLF4 TFF1
ICAM1 MUC6
INHBA RARB
LOXL2 SMAD4
MCM3
PTMA
SPARC
1Previously reported overexpressed proteins for gastric cancer which were
also overexpressed in our microdissected (LCM) and macrodissected cancer
samples as compared with normal samples
2Previoulsy reported underexpressed proteins for gastric cancer which were
also underexpressed in our microdissected (LCM) cancer samples, but not in
macrodissected cancer samples
Figure 4 Representative TFF1 immunohistochemical staining
results for (A) a gastric adenocarcinoma demonstrating the
loss of TFF1 expression, and (B) normal gastric mucosa from a
healthy volunteer expressing TFF1 in gastric epithelial cells.
(Magnification = 200x)
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Page 9 of 11stromal component and positively effected the selection
of down-regulated genes [26]. Our data confirms and
extends previous observations by providing further evi-
dence that downregulated genes identified by using
microdissected material are likely to represent transcrip-
tional changes specific to the epithelial tumor compart-
ment and enriched for potential tumor suppressor
genes, in keeping with the associated loss of DNA copy
number as observed by array CGH.
Thus, we suggest that macrodissection and microdis-
section may be useful for evaluating different aspects of
gastric cancer biology using DNA microarray. Although
we could not validate our microarray data using differ-
ent RNA methods such as the quantitative reverse tran-
scription polymerase chain reaction (RT-PCR), our
conclusion is supported by consistent results from mul-
tiple gene set comparison analyses. Very small amounts
of sample could be obtained by endoscopic sampling
approved by the IRB, which greatly limited the amount
of RNA that was available for analysis. Therefore, we
were unable to perform RT-PCR experiments that
would otherwise have been done. Microarray data using
the Affymetrix platform has been generally well corre-
lated to RT-PCR data in many studies [27-29]. The fact
that there was significant overlap between genes in our
signatures and the gene lists we used for comparison
provides indirect validation for our discriminatory genes.
Conclusions
The tumor sampling technique biases the microarray
results. Macrodissected samples provide a global picture
of the tumor transcriptome including contributions
from the stromal component which may be critical for
understanding tumor biology, whereas samples collected
by microdissection eliminate the stromal contribution
and are particularly useful for identifying genes whose
expression is reduced during tumorigenesis.
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